April 2023 Top Biopharma Deal: DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311 for cancer

April 2023 Top Biopharma Deal DualityBio development and commercialization deal with BioNTech for DB 1303 and DB 1311 for cancer
April 2023 Top Biopharma Deal Upfront

DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311

Highlighted Deal Financial Comps

    • Date Announced:
    • ,

      April 3, 2023

    • Total Deal Value:
    • ,

      $1.67B

    • Upfront Cash:
    • ,

      $170M

    • Upfront Equity:
    • ,

      n/a

    • Option Payments:
    • ,

      n/a

    • Total Milestones:
    • ,

      Up to $1.5B in development, regulatory, and sales milestone payments.

    • Royalties:
    • ,

      Single-digit to double-digit tiered royalties.

    • Cost & Profit Split:
    • ,

      DualityBio retains a co-development/co-promotion cost and profit/loss sharing option for DB-1311 in the U.S. market.

Deal Synopsis

    • The Asset:
    • ,

      DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.

    • Deal Structure:
    • ,

      Dev and Commercial License

    • Partnership Features:
    • ,

      Co-Development, Shared Dev Cost , Co-Promotion, Shared Promotion Cost , Options to Add Products, TAs, and/or Territories

    • Deal Details:
    • ,
      • DualityBio granted BioNTech exclusive, worldwide rights, excluding China, Hong Kong, and Macau, to develop and commercialize DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.
      • DualityBio has the option to co-develop and co-promote DB-1311 in the U.S. with cost and profit/loss sharing.
      • DualityBio will receive $170M up front and is eligible for up $1.5B in development, regulatory, and sales milestones, plus single-digit to double-digit tiered royalties.
    • Last Month:
    • ,

      Congrats to DualityBio and BioNTech for landing DealForma’s April 2023 Top Biopharma Deal. Last month’s Deal of the Month was OncoC4 – BioNTech for ONC-392. Read about it here.

      DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

      We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

DealForma Research

Explore More
Autoimmune R&D Partnerships, M&A, Ventures, and IPOs by TA - Q2 to QTD Q4 2024 Review

Autoimmune R&D Partnerships, M&A, Ventures, and IPOs by TA – Q2 to QTD Q4 2024 Review

MedTech, Device, Digital Health, Wearables – M&A, Ventures and IPOs in Q3 2024

MedTech, Device, Digital Health, Wearables – M&A, Ventures and IPOs in Q3 2024

Biopharma Therapeutics and Platforms IPO Activity - Q3 2024

Biopharma Therapeutics and Platforms IPO Activity – Q3 2024

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive